On track to implant first patients in long-term, multicenter feasibility study of the fully implantable continuous blood glucose monitor (CBGM) system in Australia in Q3 2025 Investigational Device Ex ...

Net Loss: Net loss for the first quarter of 2025 was $6.8 million compared to a net loss of $2.9 million for the first quarter of 2024. The increase in net loss is attributable primarily to the ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

The global In Vitro Diagnostics Market is projected to be valued at USD 108.3 billion in 2024 and reach USD 150.13 billion by ...

CCS has saved more than $10 million in taxpayer dollars through the use of PropheSee, its predictive analytics platform, ...

Why: Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of common stock of West Pharmaceutical Services, Inc. (NYSE: WST ) ...

Dental floss embedded with saliva sensors detects cortisol accurately in real-time, providing a practical method for ...

Eli Lilly, Diabetes Canada both lobbying in Saskatchewan as the province continues to be non-committal on pharmacare deals ...

Abbott (NYSE:ABT) today announced results from real-world studies demonstrating benefits with its FreeStyle Libre CGM ...

Hypertension in adolescents (aged 10–19 years) and young adults is becoming a major global health issue, largely due to ...